Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2002

View Archived Issues

Muscle stem cells may be useful in the regeneration of dystrophic muscle

MedImmune to develop antibodies and vaccines against hMPV

Amsterdam Molecular Therapeutics licenses rights to IL-10 for ex vivo gene therapy

AERx iDMS enters phase III program

Pediatric indication approved for Zenapax

Pharmacodynamic and pharmacokinetic profile of fesoterodine

Potential new therapeutic for functional dyspepsia presented at medicinal chemistry meeting

Spanish investigators discover potent and selective inhibitor of the endocannabinoid transporter

SSR-69071 selected for development as an HLE inhibitor for respiratory diseases

Bladder-selective potassium channel openers described by Abbott and ICAgen

Orally active LH receptor agonist with efficacy in inducing ovulation in mice

Non-nephrotoxic AMPA antagonist S-34730-1 with potential in neurodegenerative diseases

Ezetimibe + statins consistently better than statin therapy alone

Keryx Biopharmaceuticals focuses resources on KRX-101 and KRX-123

Improved renal function associated with TA-0201 + enalapril in dogs with CHF

Tadalafil receives positive recommendation in Australia

FDA issues approvable letter for aripiprazole

Once-weekly risedronate approved in Sweden

Bayer and Boehringer Ingelheim sign letter of intent for marketing of telmisartan

A.P. Pharma withdraws APF-112 phase II protocol

Potential of fidarestat in diabetic retinopathy emerges from preclinical studies

Compounds with the ability to inhibit phosphorylation of STAT6 claimed by Pola

Merck & Co. discloses HIV integrase inhibitors

Compounds for glaucoma and ocular hypertension with improved profile over natural prostaglandins

Novel radiopharmaceuticals for imaging sites of infection and/or inflammation

Antibacterial carbapenems described by Sumitomo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 2, 2025.
Researchers arm CAR T cells to fight solid tumors
BioWorld
Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the...
Bioversys, Shionogi in CHF529M lung infection collaboration
BioWorld Science
Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on...
Medtronic receives CE mark for its Vitalflow ECMO system
BioWorld MedTech
Medtronic plc received a CE mark for its Vitalflow extracorporeal membrane oxygenation (ECMO) system, which provides temporary support for the heart and lungs in...